- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Pfizer to Buy Injectables Giant Hospira
With several of it's blockbusters going off-patent soon, Pfizer is looking at new avenues for expanding it's revenue.
Pfizer has agreed to acquire Hospira, a big maker of injectable drugs, for $15.2 billion. The acquisition is the first major deal for Pfizer since last year’s failed attempt to buy AstraZeneca for more than $100 billion.
Pfizer said on Thursday that it would pay $90 a share for Hospira, which makes infusion technologies and drugs that are injected. Including debt, the deal is valued at about $17 billion.
“The proposed acquisition of Hospira demonstrates our commitment to prudently deploy capital to create shareholder value and deliver incremental revenue and [earnings per share] growth in the near term,” Ian Read, Pfizer’s chief executive, said in a statement.
Link to the news on The New York Times:
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
